These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 35245739)
1. Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster. Mao L; Xu L; Wang X; Xing Y; Wang J; Zhang Y; Yuan W; Du J; Shi Z; Ma J; Zhang J; Zhang X; Wang X Tuberculosis (Edinb); 2022 May; 134():102186. PubMed ID: 35245739 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680 [TBL] [Abstract][Full Text] [Related]
3. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine. Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X Front Immunol; 2020; 11():575504. PubMed ID: 33117374 [TBL] [Abstract][Full Text] [Related]
4. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells. Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Immunogenicity and Mao LR; Du JP; Wang XC; Xu LF; Zhang YP; Sun QS; Shi ZL; Xing YR; Su YX; Wang SJ; Wang J; Ma JL; Zhang JY ACS Infect Dis; 2023 Mar; 9(3):593-608. PubMed ID: 36808986 [TBL] [Abstract][Full Text] [Related]
6. Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity. Shi Z; Zhou L; Wang X; Zhang Z; Kong L; Zhang Y Arch Microbiol; 2024 Jul; 206(8):352. PubMed ID: 39012499 [TBL] [Abstract][Full Text] [Related]
7. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N Front Immunol; 2018; 9():310. PubMed ID: 29535714 [TBL] [Abstract][Full Text] [Related]
8. Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against Ullah N; Hao L; Wu Y; Zhang Y; Lei Q; Banga Ndzouboukou JL; Lin X; Fan X J Immunol Res; 2020; 2020():2083793. PubMed ID: 32953889 [TBL] [Abstract][Full Text] [Related]
9. A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation. Ma J; Teng X; Wang X; Fan X; Wu Y; Tian M; Zhou Z; Li L EBioMedicine; 2017 Aug; 22():143-154. PubMed ID: 28711483 [TBL] [Abstract][Full Text] [Related]
10. Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants. Zhang Z; Xu L; Wang X; Kong L; Shi Z; Zhong Q; Xu Y; Wang J Tuberculosis (Edinb); 2024 Mar; 145():102480. PubMed ID: 38278100 [TBL] [Abstract][Full Text] [Related]
11. Potentiation of Th1-Type Immune Responses to Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214 [TBL] [Abstract][Full Text] [Related]
12. Cationic pH-sensitive liposome-based subunit tuberculosis vaccine induces protection in mice challenged with Mycobacterium tuberculosis. Szachniewicz MM; van den Eeden SJF; van Meijgaarden KE; Franken KLMC; van Veen S; Geluk A; Bouwstra JA; Ottenhoff THM Eur J Pharm Biopharm; 2024 Oct; 203():114437. PubMed ID: 39122053 [TBL] [Abstract][Full Text] [Related]
13. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice. Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736 [TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175 [TBL] [Abstract][Full Text] [Related]
15. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis. Singh S; Saraav I; Sharma S Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592 [TBL] [Abstract][Full Text] [Related]
16. The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. Kao FF; Mahmuda S; Pinto R; Triccas JA; West NP; Britton WJ PLoS One; 2012; 7(5):e34991. PubMed ID: 22567094 [TBL] [Abstract][Full Text] [Related]
17. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853 [TBL] [Abstract][Full Text] [Related]
18. Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Kwon KW; Kang TG; Lee A; Jin SM; Lim YT; Shin SJ; Ha SJ Immune Netw; 2023 Apr; 23(2):e16. PubMed ID: 37179749 [TBL] [Abstract][Full Text] [Related]
19. Heterologous Boost Following Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X Front Immunol; 2018; 9():2439. PubMed ID: 30425711 [TBL] [Abstract][Full Text] [Related]